News and Announcements
VANTARI EXPANDS FOOTPRINT
- Published January 26, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Vantari is officially across 4 hospitals nationally with Nepean Hospital coming on board as their latest customer. Driven by the Head of the Intensive Care Unit (ICU), Dr. Sam Orde, the software will be used by clinicians and junior trainees in the unit to practice medical procedures prior to performing them on real patients, reducing complications and error rates. Dr. Orde’s first impression? “It was incredible to see Vantari’s system and dream of the possibilities that open up to us”.
The three-year partnership will play a key role in kick starting the new phase of healthcare delivery in the Penrith region, given that the NSW Government has committed $550 million for Stage 1 of the Nepean Hospital Redevelopment which is expected to finish later this year. The upgrades will include a new expanded emergency department, a neonatal ICU as well as a hub for research and innovation – the perfect setting for implementation and expansion of virtual reality training.
Vantari will leverage the long-term partnership to build product capabilities, grow its user base and scale across other units at the hospital as well as grow into the larger Nepean Blue Mountains Local Health District, which covers 5 other training hospitals.
The future is bright.
About Vantari VR
Vantari is Virtual Reality training for Healthcare. They help doctors and students practice and perfect clinical procedures in VR in order to reduce medical error and save patient lives. Founded by clinicians in 2017, Vantari has positioned itself as the number 1 medical VR company in Australia with partnerships with major tertiary hospitals including Royal Prince Alfred Hospital, Westmead Hospital and Fiona Stanley Hospital.
They are a B2B SAAS business with a scalable digital platform which combines standardised learning with performance tracking to establish a new gold standard of procedural training. Their user engagement/satisfaction is >95% when compared to incumbents such as mannequins and cadavers which are unrealistic and do not mimic real life scenarios or complications. Their platform addresses all of these pitfalls and aligns with college guidelines to also reduce the subjective learning that occurs from traditional apprenticeship.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
